臺灣博碩士論文加值系統

女貞子是木犀科植物女貞（Ligustrum lucidium）之乾燥成熟果實，在傳統醫藥歸類於補益功能之常用生藥。本研究係探討女貞子乙醇萃取物對高劑量苯甲醇丁酯（Butylated hydroxytoluene，BHT）所誘發大鼠急性氧化壓力之保護作用評估。動物實驗模式將大鼠分為溶媒控制組（10 mL/kg 橄欖油）及誘發組（1000 mg/kg BHT），分別連續七天給予大鼠純水後，再分別管餵10 mL/kg 橄欖油及1000 mg/kg BHT來誘發大鼠急性氧化壓力；而藥物組則以三種不同劑量之女貞子（250、500及1000 mg/kg）來替代，再管餵1000 mg/kg之BHT。由結果顯示，與誘發組相比，女貞子乙醇萃取物能有效降低大鼠血清GPT、GOT、Alk-P、BUN、Creatinine（Cr）、LDH、Triglyceride（TG）與肺部灌流液LDH之含量，並能改善肝、肺組織脂質過氧化之程度（P < 0.05）。由組織病理切片觀察得知，女貞子乙醇萃取物可減輕大鼠肺部組織之損傷，此外，女貞子乙醇萃取物亦能有效提升大鼠肝、腎、肺臟中的抗氧化酵素之活性，如Catalase、SOD及GSH-Px等（P < 0.05），進而達到預防氧化壓力引起的器官損傷。因此，給予女貞子乙醇萃取物可藉其抗氧化壓力作用來預防BHT所引起的氧化傷害。

Nüzhenzi (NZZ) is a dry fruit of Ligustrum lucidum Ait. (Oleaceae) that applied as tonic for kidney, liver and commonly prescribed in traditional Chinese medicine. The aim of this study was to investigate the effects of ethanol extract of fruit of L. lucidum (ELL) on butylated hydroxytoluene (BHT)-induced oxidative stress in rats. Animals were pre-treated with ELL (250, 500 and 1000 mg/kg/day, orally) for seven days, and then administrated with BHT (1000 mg/kg) by oral. Compared to the BHT (1000 mg/kg)-treated group, results showed that ELL could significantly reduce the levels of serum glutamic pyruvic transaminase (GPT), glutamic oxaloacetic transaminase (GOT), alkaline phosphatase (Alk-P), blood urea nitrogen (BUN), creatinine (Cr), lactate dehydrogenase (LDH) and triglyceride (TG), as well as LDH in BALF. It also significantly decreased the level of lipid peroxidation in liver and lung. In addition, ELL also significantly enhanced the levels of catalase, superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in liver, kidney and lung tissues in rats when compared with the BHT-induced group (P < 0.05). Finally, the histopathological evaluation of the tissues revealed that ELL reduced the incidence of lung lesions. According to the results, the protective effect of ELL against acute BHT-induced oxidative stress in rats could be through its antioxidative activities and the upregulation of antioxidative enzymes.

中文摘要 ---------------------------------------------- I
英文摘要 --------------------------------------------- II

第ㄧ章 序論 ------------------------------------------- 1

第二章 女貞子 ----------------------------------------- 3
第一節 前言 ----------------------------------------- 3
第二節 藥品與器材 ----------------------------------- 4
第三節 製備流程 ------------------------------------- 5
第四節 產率 ----------------------------------------- 6

第三章 女貞子體外清除超氧陰離子自由基及抑制自由基生成之活性評估 --- 7
第一節 前言 ----------------------------------------- 7
第二節 藥品與器材 ----------------------------------- 8
第三節 實驗方法 ------------------------------------- 10
第四節 結果 ----------------------------------------- 12

第四章 女貞子體外抗脂質過氧化（Lipid peroxidation）活性之測定 --- 13
第一節 前言 ----------------------------------------- 13
第二節 藥品與器材 ----------------------------------- 14
第三節 實驗方法 ------------------------------------- 16
第四節 結果 ----------------------------------------- 19

第五章 女貞子之乙醇萃取物對苯甲醇丁酯（Butylated hydroxytoluene，BHT）所引起的大鼠急性氧化性損傷之保護作用評估 --- 20
第一節 前言 ----------------------------------------- 20
第二節 藥品與實驗動物 ------------------------------- 22
第三節 實驗方法 ------------------------------------- 23
第一項 血清及肺部灌流液之生化檢測 ----------------- 25
第二項 組織切片及均質液之製作 --------------------- 26
第四節 結果 ----------------------------------------- 27

第六章 肝臟、腎臟與肺臟組織中抗氧化酵素及脂質過氧化物含量之檢測 --- 28
第一節 前言 ----------------------------------------- 28
第二節 超氧化物歧化酶（Superoxide dismutase，SOD）含量之測定 ---30
第一項 原理 ----------------------------------------- 30
第二項 藥品與器材 ----------------------------------- 31
第三項 實驗方法 ------------------------------------- 33
第四項 結果 ----------------------------------------- 35
第三節 過氧化氫酶（Catalase；CAT）活性試驗 ---------- 36
第一項 原理 ----------------------------------------- 36
第二項 藥品與器材 ----------------------------------- 37
第三項 實驗方法 ------------------------------------- 38
第四項 結果 ----------------------------------------- 40
第四節 谷胱甘肽過氧化物酶（Glutathione peroxidase，GSH-Px）活性試驗 - 41
第一項 原理 ----------------------------------------- 41
第二項 藥品與器材 ----------------------------------- 42
第三項 實驗方法 ------------------------------------- 45
第四項 結果 ----------------------------------------- 47
第四節 脂質過氧化（Lipid peroxidation）含量之測定 --- 48
第一項 原理 ----------------------------------------- 48
第二項 藥品與器材 ----------------------------------- 49
第三項 實驗方法 ------------------------------------- 51
第四項 結果 ----------------------------------------- 53

第七章 統計學分析 ------------------------------------- 54

第八章 討論 ------------------------------------------- 55

第九章 結論 ------------------------------------------- 59

參考文獻 ---------------------------------------------- 60

附表 -------------------------------------------------- 65

附圖 -------------------------------------------------- 71

投稿與學會發表論文 ------------------------------------ 87

1.林俊清。應用生藥學（I）生藥與自由基。富山出版社。1995，p.1-9。
2.Cerutti P.A., Prooxidant states and tumor promotion, Science, 1985, 25, 227(4685), 375-81.
3.Lavrovsky Y., Chatterjee B., Clark R.A. and Roy A.K., Role of redox-regulated transcription factors in inflammation, aging and age-related diseases, Exp. Gerontol., 2000, 35, 521–32.
4.Shi L., Ma Y. and Cai Z., Quantitative Determination of Salidroside and Specnuezhenide in the Fruits of Ligustrum lucidum Ait. by High Performance Liquid Chromatography, Biomed. Chromatogr., 1998, 12, 27–30.
5.He Z.D., But P.P.H., Chan T.W., Dong H., Xu H.X., Lau C.P. and Sun H.D., Antioxidative Glucosides from the Fruits of Ligustrum lucidum, Chem. Pharm. Bull., 2001, 49(6), 780-4.
6.Liu H., Shi Y., Wang D., Yang G., Yu A. and Zhang H., MECC determination of oleanolic acid and ursolic acid isomers in Ligustrum lucidum Ait. J. Pharm. Biomed. Anal., 2003, 32, 479-85.
7.He Z.D., Dong H., Xu H.X., Ye W.C., Sun H.D. and But P.P., Secoiridoid constituents from the fruits of Ligustrum lucidum., Phytochemistry, 2001 ,56, 327-30.
8.駱和生，羅鼎輝。免疫中藥學-中藥免疫藥理與臨床。北京大學醫學出版社，1999，p.103-7。
9.應小雄，虞厚安。中華本草。上海科學技術出版社。1999，6，p.183-9。
10.許世凱，呂明方。抗衰老藥物學。中國醫藥科技出版社。1992，p.40-6，231-49，355-7。
11.肖培根。新編中藥志。中國華僑出版社。2002，2，p.61-9。
12.Yim T.K., Wu W.K., Pak W.F. and Ko K.M., Hepatoprotective action of an oleanolic acid-enriched extract of Ligustrum lucidum fruits is mediated through an enhancement on hepatic glutathione regeneration capacity in mice. Phytother. Res., 2001, 15(7), 589-92.
13.鄭虎占，董澤宏，佘靖。中藥現代研究與應用。學苑出版社，1997，1，p.724-49。
14.McCord J.M. and Fridovich I., Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein), J. Biol. Chem., 1969, 244(22), 6049-55.
15.丁克祥，邱仲峰，呂鋒洲。SOD生物醫學淺論。藝軒圖書出版社，1996，p.3-6，4-12，25-32。
16.Ohkawa H., Ohishi N. and Yagi K., Assay for lipid peroxides in animal tissue by thiobarbituric acid reaction, Anal. Biochem., 1979, 95, 351-8.
17.Kimuya Y., Kubo M., Tani T., Arichi S. and Okuda H., Studies on Scutellariae Radix. IV. Effects on lipid peroxidation in rat liver, Chem. Pharm. Bull., 1981, 29(9), 2610-7.
18.Lowry O.H., Rosebrough N.J., Farr A.L. and Randall R.J., Protein measurement with the Folin phenol reagent, J. Biol. Chem., 1951, 193(1), 265-75.
19.Lanigan R.S. and Yamarik T.A., Final report on the safety assessment of BHT(1), Int. J. Toxicol., 2002, 2, 19-94.
20.吳淑靜，柯文慶，賴滋漢。食品添加物。富林出版社。1997，p.143-62。
21.Witschi H., Malkinson A.M. and Thompson J.A., Metabolism and pulmonary toxicity of butylated hydroxytoluene (BHT), Pharmacol. Ther., 1989, 42(1), 89-113.
22.Reed M., Fujiwara H. and Thompson D.C., Comparative metabolism, covalent binding and toxicity of BHT congeners in rat liver slices, Chem. Biol. Interact., 2001, 138, 155–70.
23.Powell C.J. and Connolly A.K., The site specificity and sensitivity of the rat liver to butylated hydroxytoluene-induced damage, Toxicol. Appl. Pharmacol., 1991, 15, 108(1), 67-77.
24.Marino A.A. and Mitchell J.T., Lung damage in mice following intraperitoneal injection of butylated hydroxytoluene, Proc. Soc. Exp. Biol. Med., 1972, 140(1), 122-5.
25.Witschi H.and Lock S., Toxicity of butylated hydroxytoluene in mouse following oral administration, Toxicology, 1978, 9, 137-46.
26.Takahashi O., Haemorrhages due to defective blood coagulation do not occur in mice and guinea-pigs fed butylated hydroxytoluene, but nephrotoxicity is found in mice. Food Chem. Toxicol., 1992, 30(2), 89-97.
27.Sun Y., Dwyer-Nield L.D., Malkinson A.M., Zhang Y.L. and Thompson J.A., Responses of tumorigenic and non-tumorigenic mouse lung epithelial cell lines to electrophilic metabolites of the tumor promoter butylated hydroxytoluene, Chem. Biol. Interact., 2003, 6, 145(1), 41-51.
28.Mizutani T., Nomura H., Yamamoto K. and Tajima K., Modification of butylated hydroxytoluene-induced pulmonary toxicity in mice by diethyl maleate, buthionine sulfoximine, and cysteine, Toxicol. Lett., 1984, 23(3), 327-31.
29.Bolton J.L., Thompson J.A., Allentoff A.J., Miley F.B. and Malkinson A.M., Metabolic activation of butylated hydroxytoluene by mouse bronchiolar Clara cells, Toxicol. Appl. Pharmacol., 1993, 123(1), 43-49.
30.Nakagawa Y., Tayama K., Nakao T. and Hiraga K., On the mechanism of butylated hydroxytoluene-induced hepatic toxicity in rats, Biochem. Pharmacol., 1984, 15, 33(16), 2669-74.
31.徐勤。抗衰老研究方法。中國醫藥科技出版社。1996，p. 459-60。
32.Beauchamp C. and Fridovich I., Superoxide dismutase: improved assays and an assay applicable to acrylamide gels, Anal. Biochem., 1971, 44(1), 276-87.
33.Aebi H., Catalase in vitro, Meth. Enzymol., 1984, 105, 121-6.
34.Flohe L. and Gunzler W.F., Assays of glutathione peroxidase, Meth. Enzymol., 1984, 105, 114-21.
35.Hickey E.J., Raje R.R., Reid V.E., Gross S.M. and Ray S.D., Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death, Free Radic. Biol. Med., 2001, 15, 31(2), 139-52.
36.Rajesh M.G. and Latha M.S., Preliminary evaluation of the antihepatotoxic activity of Kamilari, a polyherbal formulation, J. Ethnopharmacol., 2004, 91(1), 99-104.
37.Yanardag R. and Tunali S., Vanadyl Sulfate Administration Protects the Streptozotocin-Induced Oxidative Damage to Brain Tissue in Rats, Mol. Cell Biochem., 2006, 11, [Epub ahead of print].
38.Erdem A., Gundogan N.U., Usubutun A., Kilinc K., Erdem S.R., Kara A. and Bozkurt A., The protective effect of taurine against gentamicin-induced acute tubular necrosis in rats, Nephrol. Dial. Transplant., 2000,15(8), 1175–82.
39.Bartus M., Lomnicka M., Lorkowska B., Franczyk M., Kostogrys R.B., Pisulewski P.M. and Chlopicki S., Hypertriglyceridemia but not hypercholesterolemia induces endothelial dysfunction in the rat, Pharmacol. Rep., 2005, 57, 127-37.
40.Oh P.S., Lee S.J. and Lim K.T., Hypolipidemic and Antioxidative Effects of the Plant Glycoprotein (36 kDa) from Rhus verniciflua Stokes Fruit in Triton WR-1339-Induced Hyperlipidemic Mice, Biosci. Biotechnol. Biochem., 2006, 70(2), 447-56.
41.Hassan H.M., Biosynthesis and regulation of superoxide dismutases, Free Radic. Biol. Med., 1988, 5(5-6), 377-85.
42.Rajasekaran S., Sivagnanam K. and Subramanian S., Antioxidant effect of Aloe vera gel extract in streptozotocin-induced diabetes in rats, Pharmacol. Rep., 2005, 57(1), 90-6.
43.Jung C.H., Seog H.M., Choi I.W., Choi H.D. and Cho H.Y., Effects of wild ginseng (Panax ginseng C.A. Meyer) leaves on lipid peroxidation levels and antioxidant enzyme activities in streptozotocin diabetic rats, J. Ethnopharmacol., 2005, 26, 98(3), 245-50.
44.Selvakumar E., Prahalathan C., Mythili Y. and Varalakshmi P., Protective effect of DL-alpha-lipoic acid in cyclophosphamide induced oxidative injury in rat testis, Reprod. Toxicol., 2004, 19(2), 163-7.
45.戴岳。中國中藥雜誌。中國中藥雜誌社。1989，14(7)，p. 431。
46.熊曉玲。中國實驗臨床免疫學雜誌。北京。1991，3(4)，p. 37。
47.宋京。中草藥。天津藥物研究院。1999，30，p. 196-7。
48.Stierum R., Heijne W., Kienhuis A., van Ommen B. and Groten J., Toxicogenomics concepts and applications to study hepatic effects of food additives and chemicals, Toxicol. Appl. Pharmacol., 2005, 207(2), 179-88.
49.Yoshida Y., Study on mutagenicity and antimutagenicity of BHT and its derivatives in a bacterial assay, Mutat. Res., 1990, 242(3), 209-17.
50.Malkinson A.M., Radcliffe R.A. and Bauer A.K., Quantitative trait locus mapping of susceptibilities to butylated hydroxytoluene-induced lung tumor promotion and pulmonary inflammation in CXB mice, Carcinogenesis, 2002, 23(3), 411-7.